

# Transaction Update

7<sup>th</sup> September 2021

## Progress since previous update

#### Inificant progress has been made

e the previous update to this committee, there have been significant inroads towards the completion of the saction, and <mark>there now remain no significant risks to transaction completion</mark>. SRFT and PAT have worked closely value in the submit a range of documentation and undergo a number of review meetings.

#### Strategic Rationale

All submissions made noluding updated annual plan, collaboration action plan, updated patient penefits with further nput from PAT Executive, updated paper linking capital expenditure with patient and financial penefits.

Strong working relationships have developed further with MFT, PAT and system stakeholders.

#### Transaction Execution

- Updated documents submitted and detailed updates on Orthoplastics and Cancer provided to Quality Review meeting as well as PAT, previous stocktake meetings.
- Disaggregation progressing well between providers with follow on steps or statements of intent agreed.
- Post Transaction Governance agreed including Legacy Management office.

#### Finance

- Finance updates submitted and is in review,
- Revised LTFM submitted
- Key assumptions signed off through Finance Working Group and shared with regional team
- Reporting accountant: line of sight review completed and submitted to Board, summary provided in deck.

#### Quality

- All documentation submitted
- Oldham CQC improvement plan on track
- One remaining STP with Amber QIA (OMFS – MFT service)
- Detailed Quality review and session completed

### number of key meetings have taken place

RFT have undertaken a number of meetings with the NHSEI review team as part etransaction progress. The NHSEI review team have also met with PAT elleagues. These meetings have been positive and constructive.

RFT and PAT executives and non-executives have met regularly to discuss the elivery of services under the management agreement and operational issues.

ne NHSEI review team will submit their recommendations on the transaction to the ovider Oversight Committee on 14<sup>th</sup> September 2021.

## e reduced risk to transaction delivery

a result of the transaction being phased, there have been additional opportunities to reduce any remainin as prior to transaction taking place.

ere remain no significant risks to transaction completion. There is one risk scored at 10 as follows:

Financial and operational performance falling across both SRFT and PAT may fall further before the transaction takes place; mitigation of continuing QI programmes and Oldham CQC improvement plan

erms of operational risks following transaction, there remains one risk rated at 10:

Capital funding for transformation; discussions are ongoing between NCA and NHSEI NW / other system stakeholders. We expect this risk to be closed as part of the agreement of the ICS capital control total for 2022/23.

e current risk position is described in the table below.

	Open risk position: August 2020 (at BC submission)			Open risk position: end August 2021				
Туре	12+	11-10	9-5	>5	12+	11-10	9-6	>5
Risk to Transaction	7	6	13	0	0	1	2	0
Operational	1	5	15	0	0	1	16	0

# Post-Transaction Changes and Impacts on Patients

#### ere will be limited changes post-transaction

mediately following transaction, there will be no changes to any services. Our key focus Il be the delivery of a "safe landing" for all services and for patients in order to ensure a amless transition to the new organisation.

A exit timetables have been agreed between NCA and MFT. Exit plans have been agreen the SLAs concluding in September 2021 following the NCA transaction completion, with any for the rest in development. There may be some changes as services disaggregate, and relevant partners will be engaged as appropriate.

e key visible change will be the organisational name change from SRFT / PAT to Northe are Alliance NHS Foundation Trust. A new email address will be put in place for all staff of transaction, ending @nca.nhs.uk rather than @srft.nhs.uk or @pat.nhs.uk. Existing ema Idresses will continue to operate for an extended period of time.

ur new NCA website (<u>www.northerncarealliance.nhs.uk</u>) will be launched on 1 October c T and SRT old websites decommissioned. Public, patients and external stakeholders w able to access all information as before in one place and updated content and guidan

e four Care Organisations (Bury, Oldham, Rochdale, Salford) will continue to have distinentities, and with no changes to the leadership or clinical teams.

#### aggregation Plan beyond September 2021

ervice Disaggregation and LA Exit at 1 April 2022	Service Disaggregation at 1 October 2022	Service Disaggregation Beyond 12 months (timing dependent on external factors)	Service where Nature / Timescale / whether to Disaggregate needs Further Consideration
xit Plan developed by Sept 021	Exit Plan developed by Sept 2021	Plan on a Page developed by Sept 2021	Statement of Intent developed by Sept 2021
iabetes / Endocrin	IT / Informatics	Vascular Surgery	Gastroenterology (Disagg March 23)
ardiology (ex Cath Lab)	Pathology	Gynaecology	General Surgery
alliative Medicine & haplaincy	Pharmacy (Some staff transfer at March 22)		Urology
ancer Trackers etc	Therapies (Audiology)		Trauma and Ortho
phthalmology	Switchboard		ENT
terp / Translation			Cardiology Cath Lab
aundry & Linen			Clin Haematology
			Rheumatology

## ganisational Capacity

part of routine assessment processes in preparation for a transaction, NHSEI asked the sestion "how does the Board ensure that it has the right bandwidth to deliver BAU and the sy strategic agenda the organisation has, including the transaction?". This question has en posted particularly in the context of COVID and COVID recovery

paper was considered by Group Board on 26th July outlining how the Board assesses indwidth against objectives & requirements, and what is being put in place to deliver ese, so that it can assure NHSEI that appropriate oversight and risk assessment is dertaken to match bandwidth to objectives & requirements.

is will ensure that there is enough capacity to deliver patient benefits through existing ogrammes of work alongside dedicated programme management capacity for saggregation.

ontingencies are able to be quickly set up in case of capacity gaps.

## rutiny Arrangements

s not anticipated that there will be any changes to the overall scrutiny rangements between NCA and local authority partners as a result of transaction mpletion. The NCA will continue to proactively engage with local authorities and trutiny committees as valued partners.

nere will however inevitably be a reduction in focus on the transaction itself and creased attention on the disaggregation of services and their impact on patients cal residents.

ne Pennine-wide scrutiny arrangements are due to be discussed at the Joint ealth Overview & Scrutiny Committee on 6<sup>th</sup> September.